Patents Assigned to DCPrime B.V.
-
Patent number: 11071778Abstract: The present invention relates to a combination product for use in eliciting an immune response against a tumor in a subject, said product comprising: —an immunogenic composition comprising a non-human antigenic polypeptide as an immunogen, or comprising a nucleic acid encoding said immunogen, and optionally one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents; and—said non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide; wherein said polypeptide or said nucleic acid is prepared for intratumoral delivery. The invention also provides fusion proteins and protein-protein conjugates that can be used in the medical methods described herein.Type: GrantFiled: April 24, 2020Date of Patent: July 27, 2021Assignee: DCPRIME B.V.Inventors: Erik Hans Manting, Satwinder Kaur Singh, Adriana Maria Kruisbeek, Vinod Sommandas
-
Patent number: 11052144Abstract: A method for treating a tumor or generating an immune response against a tumor in a subject in need including a vaccination step comprising administration of a first composition, and a tumor-marking step comprising administration of a second composition, is provided. The first and second composition each comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. Also provided are antigenic polypeptides and compositions for use in methods described herein.Type: GrantFiled: April 24, 2020Date of Patent: July 6, 2021Assignee: DCPRIME B.V.Inventors: Erik Hans Manting, Satwinder Kaur Singh, Vinod Sommandas
-
Patent number: 11027001Abstract: The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012.Type: GrantFiled: August 10, 2018Date of Patent: June 8, 2021Assignee: DCPRIME B.V.Inventors: Sandra Van Wetering, Adriana Kruisbeek
-
Patent number: 10064923Abstract: The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012.Type: GrantFiled: December 10, 2013Date of Patent: September 4, 2018Assignee: DCPRIME B.V.Inventors: Sandra Van Wetering, Adriana Marie Kruisbeek
-
Publication number: 20150297698Abstract: The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012.Type: ApplicationFiled: December 10, 2013Publication date: October 22, 2015Applicant: DCPRIME B.V.Inventors: Sandra Van Wetering, Adriana Marie Kruisbeek
-
Patent number: 8470789Abstract: The present invention relates to a method for the production of functional dendritic cells wherein CD34 positive cells are contacted with compounds inducing and accelerating the differentiation of these CD34 positive cells into functional dendritic cells. More in particular, the CD34 positive cells are contacted with anthracyclines and/or anthracenediones. In another aspect, the current invention relates to the cells obtainable by the method according to the invention. In a further aspect the current invention relates to the use of compounds such as anthracyclines and/or anthracenediones that induce and accelerate the differentiation of CD34 positive cells into functional dendritic cells in the manufacture of a medicament for inducing an immune response in human in need thereof.Type: GrantFiled: November 12, 2008Date of Patent: June 25, 2013Assignee: DCPrime B.V.Inventors: Sandra van Wetering, Tanja Denise de Gruijl, Adriane Marie Kruisbeek, Rieneke van de Ven, Riekeld Johannes Scheper